{"filing":{"accession_number":"0001193125-26-268415","cik":"0001612042","ticker":"ASND","company_name":"Ascendis Pharma A/S","form":"6-K","filing_date":"2026-06-12","report_date":null,"primary_document":"d136465d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526268415/d136465d6k.htm"},"events":[{"id":12141,"run_id":10706,"accession_number":"0001193125-26-268415","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The 6-K discloses positive Phase 2 clinical trial results for TransCon PTH (palopegteriparatide) in hypoparathyroidism, announced June 11, 2026. The five-year PaTH Forward Trial data demonstrates sustained efficacy and safety with high responder rates (82%), maintained kidney function improvements, and quality-of-life benefits. This is a material clinical milestone for a biopharmaceutical company's lead program, but it is not a discrete event type in the taxonomy (not earnings, M\u0026A, litigation, or other named categories). It is clearly operational—a significant product development and regulatory milestone—making `operational_other` the best fit.","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-06-12","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":8920,"accession_number":"0001193125-26-268415","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The 6-K discloses positive Phase 2 clinical trial results for TransCon PTH (palopegteriparatide) in hypoparathyroidism, announced June 11, 2026. The five-year PaTH Forward Trial data demonstrates sustained efficacy and safety with high responder rates (82%), maintained kidney function improvements, and quality-of-life benefits. This is a material clinical milestone for a biopharmaceutical company's lead program, but it is not a discrete event type in the taxonomy (not earnings, M\u0026A, litigation, or other named categories). It is clearly operational—a significant product development and regulatory milestone—making `operational_other` the best fit.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:18:53.831759+00:00","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-06-12"}]}